People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD). According to the company, approval was supported by a pivotal placebo-controlled ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as mental health medicine. A recent approval made by the FDA could be a great step ...

Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

"SPRAVATO ® is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral ...

“Spravato is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days — without the need for daily oral ...

The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.